Drugs / LNS8801
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04130516 | Oct 2019 → Jun 2026 overdue | cancer | Linnaeus Therapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06624644 | Aug 2025 → Feb 2029 expected | cutaneous melanoma | Linnaeus Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LNS8801 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06624644 ↗ |
| Known as | CHEMBL569766 | ChEMBL registry synonym — accepted as the source's own label CHEMBL569766 ↗ |
| Known as | ML051 | ChEMBL registry synonym — accepted as the source's own label CHEMBL569766 ↗ |
| Action | Activate | “selective agonist of GPER” NCT04130516 ↗ |
| Modality | Small molecule | — CHEMBL569766 ↗ |
| Route | Oral | “LNS8801 will be administered orally” NCT04130516 ↗ |
| Target | GPER | “selective agonist of GPER” NCT04130516 ↗ |